Sanofi has struck a deal to buy Synthorx for $2.5 billion (€2.3 billion). The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi control of an IL-2 drug it thinks can become a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results